IP Library Granted Patent US 9,243,052
Granted Patent B2
US 9,243,052 · App. 12/673,721 · Granted Jan 26, 2016

Method for treating and diagnosing hematologic malignancies

Inventors: Daniel Olive (Marseilles, FR); Luc Xerri (Marseilles, FR); Alemseged Truhneh (Sudbury, MA)
C07K14/70521C07K14/4747C07K16/2818C07K16/2827G01N33/57426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,243,052
App. No.
12/673,721
Granted
Jan 26, 2016
Kind
B2
Abstract

The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2, or anti-PD-1 antibodies).

Claims (4)

1. A method for treating a hematologic malignancy, comprising the administration of a ligand of PD1, wherein said ligand of PD1 is an anti-PD1 monoclonal antibody or an antigen binding fragment thereof which binds to PD1 and induces death and/or elimination of a B-cell expressing PD1,

said monoclonal antibody being selected from the group consisting of a monoclonal antibody obtainable from a hybridoma deposited at the COLLECTION NATIONALE DE CULTURES DE MICROORGANISMES (CNCM) as CNCM I-3745 and a monoclonal antibody comprising the three complementary determining regions (CDRs) from each of the heavy and light chain variable regions of the monoclonal antibody obtainable from hybridoma CNCM I-3745, and

said antigen binding fragment comprising a sequence of the monoclonal antibody obtainable from hybridoma CNCM I-3745 that comprises at least the three light chain CDRs and the three heavy chain CDRs of the monoclonal antibody, and

wherein the hematologic malignancy is selected from the group consisting of a chronic lymphocytic leukemia of B-cell origin and a small lymphocytic lymphoma of B-cell origin.

Priority Claims (1)
EP 07301312 · Aug 17, 2007 · regional
Continuity (1)
Related Publication 20110177088A1 · Jul 21, 2011